GEFITINIB TABLETS IP 250 MG (GEFTICIP)

Q1: What is Gefitinib 250mg (Gefticip) used for?

Gefitinib is an EGFR tyrosine kinase inhibitor (TKI) approved for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with EGFR mutations (exon 19 deletions or exon 21 L858R substitution). In HIV patients, it manages co-existing lung cancer.

Q2: How does Gefitinib work against lung cancer?

Gefitinib selectively inhibits the EGFR (Epidermal Growth Factor Receptor) tyrosine kinase. In EGFR-mutant NSCLC, EGFR drives uncontrolled cell proliferation. Blocking EGFR signaling halts tumor cell growth and promotes apoptosis in EGFR-dependent cancer cells.

Q3: What EGFR test is required before starting Gefitinib?

Tumor tissue testing (or liquid biopsy) for EGFR mutations is mandatory before starting Gefitinib. It is only effective in EGFR-mutant NSCLC — specifically exon 19 deletion or exon 21 L858R mutation. Patients without these mutations should not receive Gefitinib.

Q4: How is Gefitinib 250mg taken?

Take 250mg once daily, with or without food. If a dose is missed and the next dose is less than 12 hours away, skip the missed dose. Swallow tablets whole.

Q5: What are the most common side effects?

Diarrhea (most common, affects ~50–60%), acneiform rash (paronychia, skin reactions — occurs in ~60%, often indicates efficacy), nausea, dry skin, and decreased appetite are most common.

Q6: What serious side effects require immediate medical attention?

Seek immediate care for: new or worsening respiratory symptoms (possible interstitial lung disease/pneumonitis — occurs in ~1–3% and can be fatal), severe or bloody diarrhea, severe skin blistering, or sudden vision changes (dry eye syndrome may also occur).

Q7: What is the relationship between skin rash and Gefitinib efficacy?

Interestingly, patients who develop acneiform rash on EGFR inhibitors tend to have better anti-tumor responses. The rash severity can indicate adequate drug levels and EGFR pathway inhibition.

Q8: What drug interactions affect Gefitinib?

Gefitinib is metabolised by CYP3A4. Strong CYP3A4 inducers (rifampicin, carbamazepine, phenytoin) reduce efficacy. Strong CYP3A4 inhibitors increase levels and toxicity. Gefitinib also raises warfarin INR — close monitoring needed.

Q9: How does Gefitinib interact with HIV medications?

Some HIV protease inhibitors (ritonavir, cobicistat-boosted drugs) are strong CYP3A4 inhibitors that can significantly raise Gefitinib levels and increase toxicity. Discuss HIV/cancer combination management with a team including both HIV and oncology specialists.

Q10: Is Gefitinib safe during pregnancy?

Gefitinib can cause fetal harm. It is contraindicated in pregnancy. Effective contraception is required during and for at least 1 month after treatment. Breastfeeding should be avoided during and after treatment.

Q11: How should Gefitinib 250mg be stored?

Store at room temperature away from light and moisture. Keep in original packaging out of reach of children.

Q12: Do I need a prescription for Geficip?

Yes. Gefitinib is a prescription-only oncology drug requiring confirmed EGFR mutation status, specialist prescribing, and regular monitoring of liver function and respiratory symptoms.